Kalaris Therapeutics Stock Forecast

Stock Price Forecast

According to 8 analysts polled by S&P Global, Kalaris Therapeutics stock has a consensus rating of "Buy" and an average price target of $18.71. The average 1-year stock price forecast is 313.02% higher than the current stock price, while the lowest is $7.00 (+54.53%) and the highest is $25 (+451.88%).

Price Target: $18.71 (+313.02%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$7.00	$18.71	$20	$25
Change	+54.53%	+313.02%	+341.50%	+451.88%

* Price targets were last updated on Jun 1, 2026.

Analyst Ratings

The average analyst rating for Kalaris Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	4	4	4	4	5	6
Buy	1	1	1	2	2	2
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	6	6	6	7	8	9

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Tara Bancroft TD Cowen	TD Cowen	Buy Initiates n/a	Buy	Initiates	n/a	n/a	Jun 15, 2026
Yun Zhong Wedbush	Wedbush	Buy Maintains $17	Buy	Maintains	$17	+275.28%	Jun 1, 2026
Judah Frommer Morgan Stanley	Morgan Stanley	Buy Maintains $14	Buy	Maintains	$14	+209.05%	May 13, 2026
Jonathan Wolleben Citizens JMP	Citizens JMP	Buy Maintains $26 → $25	Buy	Maintains	$26 → $25	+451.88%	May 13, 2026
Lachlan Hanbury Brown William Blair	William Blair	Buy Maintains n/a	Buy	Maintains	n/a	n/a	May 12, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

11.43M

EPS This Year

-2.03

from -2.85

EPS Next Year

-1.63

from -2.03

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-
Operating Income	-14.01M	-13.46M	-51.73M	-46.15M	-51.19M
Net Income	-15.49M	-14.70M	-69.17M	-43.44M	-49.14M
EPS	-	-	-	-2.85	-2.03
Free Cash Flow	-	-9.43M	-18.82M	-23.19M	-46.66M
No. Analysts	-	-	-	-	7

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

EPS	2026	2027	2028
High	-1.62
Avg	-2.03
Low	-2.19

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-